Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therapeutic Solutions International Inc TSOI

Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. It has developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells. It has obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE), TBI, and lung pathology.


OTCPK:TSOI - Post by User

Therapeutic Solutions International Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(250)
•••
Post by whytestockson Mar 04, 2024 1:00pm
50 Views
Post# 35913659

Therapeutic Solutions International Granted Patent on Commer

Therapeutic Solutions International Granted Patent on Commer
News; $TSOI Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune&#xAE; Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 PatientsLatest Patent to Complement Issued Claims on Viral Inhibition, Adaptive Immune Stimulation, and Brain Protection/Regeneration Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the abi...TSOI - Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune&#xAE; Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities